ABSTRACT A cell surface glycoprotein antigen with an apparent molecular weight of about 100,000 that is selectively expressed on proliferating cells was purified from deoxycholate-solubilized membranes of a cultured human leukemic thymusderived (T) cell line by affinity chromatography on a monoclonal antibody-Sepharose column. A conventional xenoantiserum prepared by immunization with the affinity-purified glycoprotein was found to contain antibodies against a serum component that bound tightly to cultured cells. This molecule was shown to be specifically associated with the cell surface glycoprotein purified by immunoprecipitation from lysates ofcells. We have identified the serum component as transferrin and conclude that the membrane glycoprotein is the cell surface transferrin receptor.
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We previously identified, by means of a monoclonal antibody designated B3/25, a human cell surface antigen that was found on most cultured human hematopoietic tumor cell lines and a variety ofnonhematopoietic tumor cell lines but was not readily detectable on the normal tissues tested (1) . The antigen was shown to be a glycoprotein with an apparent molecular weight of about 100,000 in reducing conditions on NaDodSOJpolyacrylamide gels. It probably exists as disulfide-bonded dimers in the membrane, because in nonreducing conditions its apparent molecular weight was 200,000. Expression of the glycoprotein appears to be associated with cell proliferation. Although not detected on normal resting lymphocytes, the glycoprotein was found on mitogen-stimulated cells (1) . Also, the glycoprotein was lost from the surface of HL-60, an inducible human promyelocytic tumor cell line (2) , after in vitro exposure to dimethyl sulfoxide and other inducers that cause the cells to undergo functional and morphological maturation and stop growing.
During further studies, the cell surface glycoprotein was purified from a human thymus-derived (T) leukemic cell line by affinity chromatography ofdetergent-solubilized membranes on a B3/25 monoclonal antibody-Sepharose column. Characterization of a xenoantiserum against the affinity-purified glycoprotein revealed that it unexpectedly contained antibodies against a serum component derived from the culture medium in which the cells were grown. This observation led to the experiments reported here that show that the B3/25 glycoprotein specifically binds the serum component, which was identified as transferrin. The membrane glycoprotein appears, therefore, to be the cell surface transferrin receptor.
MATERIALS AND METHODS
Cells. Human hematopoietic cell lines were maintained in RPMI 1640 medium and murine hematopoietic cells were grown in Dulbecco's modified Eagle's medium. Either 10% horse serum or 5-10% fetal calf serum was used to supplement the culture medium. RPMI 8402, CCRF-CEM, and HPB-ALL are human T leukemic cell lines (3, 4) and BW5147 is a murine T lymphoma cell line (5) . Peripheral blood mononuclear cells were isolated from defibrinated human blood by Ficoll/Hypaque gradient centrifugation (6) .
Purification of B3/25 Glycoprotein. B3/25 glycoprotein was purified from CCRF-CEM cells grown in 8-liter spinner flasks in RPMI 1640 medium supplemented with 10% horse serum. All purification steps were carried out at 40C. Cells were harvested, washed with 0.15 M NaCV/0.01 M sodium phosphate buffer (pH 7.4), resuspended in 0.13 M NaCl/0.02 M Hepes buffer (pH 7.2), and homogenized by nitrogen cavitation at 800 pounds/inch2 (5.5 MPa) for 5 min at 40C in an Artisan cavitation apparatus. Nuclei and unbroken cells were removed by centrifugation at 450 x g for 15 min and a crude membrane pellet was obtained by centrifugation at 100,000 X g for 60 min. Membranes obtained from 6 x 109 cells were solubilized in 20 ml of 2% sodium deoxycholate/0.01 M Tris HCl (pH 8.0) containing Trasylol at 100 units/ml by homogenization in a Dounce homogenizer, and insoluble material was removed by centrifugation at 100,000 X g for 60 min. The detergent extract was then applied to a 20-ml column of B3/25 monoclonal antibodySepharose. The column was washed extensively with 0.5% sodium deoxycholate/0.05% NaDodSOJ0.01 M Tris-HCl (pH 8.0) and then the bound material was eluted with 0.1% sodium deoxycholate/0.05 M diethylamine HCl (pH 11.5) and immediately neutralized to pH 8.5 by the addition of solid glycine. Approximately 370 ,ug of protein estimated by the method of Lowry (7) was recovered after the affinity chromatography step.
Immunological Reagents. Monoclonal antibodies against B3/ 25 glycoprotein, designated B3/25 and T56/14, respectively, were obtained as described previously for B3/25 monoclonal antibody (1) . T29/33 monoclonal antibody specific for the human homologue of murine T200 cell surface glycoprotein has been described elsewhere (8) . Ascitic fluid containing monoclonal antibodies was obtained from pristane-primed BALB/c mice injected intraperitoneally with 1-2 x 107 hybridoma cells. Monoclonal antibody-Sepharose containing 5-10 mg of antibody per ml of settled beads was prepared by the cyanogen bromide coupling method (9), using antibodies purified from ascitic fluid by precipitation with 50% saturated ammonium sulfate. The B3/25 monoclonal antibody was further purified by ion-exchange chromatography on DEAE-cellulose. A xenoantiserum against affinity-purified B3/25 glycoprotein was prepared in a New Zealand White rabbit by two intradermal injections, spaced 4 weeks apart, of approximately 70 ,g of the affinity-purified glycoprotein emulsified in complete Freund's adjuvant and divided among multiple sites on the back.
Cell Binding Assays. '25I-Labeled horse serum, human serum, and human transferrin (Miles) were prepared by the chloramine-T method (10) . Labeled proteins were separated from Nal25I by chromatography on Bio-Gel P-10 (Bio-Rad).
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Assuming complete recovery ofprotein, specific activities ofthe "2I-labeled proteins were 0. After incubation with 10 ,ul of "2I-labeled serum for 30 min at 4°C in 200 1,u of washing buffer, the beads were again washed three times with the same buffer. Miscellaneous Procedures. Cell surface iodination, by the glucose-oxidase modification of the lactoperoxidase technique (11), immunoprecipitation procedures using fixed Staphylococcus aureus to isolate antibody-antigen complexes, and NaDodSOjpolyacrylamide gel electrophoresis employing the discontinuous buffer system of Laemmli (12) were performed as described (13) . RESULTS
Characterization of the Rabbit Anti-B3/25 Glycoprotein Antiserum. A rabbit antiserum against B3/25 glycoprotein was prepared as described in Materials and Methods. The glycoprotein preparation used for immunization contained a major component with an apparent molecular weight of 95,000 corresponding to the B3/25 glycoprotein together with small amounts of lower molecular weight species (Fig. 1) . By fluorescence-activated cell analysis, the specificity of the xenoantiserum appeared to be similar to that of the B3/25 monoclonal antibody. While cultured T leukemic cells were strongly stained by the xenoantiserum, peripheral blood mononuclear cells and induced HL-60 cells were negative. Immunoprecipitation studies, however, showed that the xenoantiserum precipitated an 80,000 Mr species from lysates of iodinated T leukemic cells in addition to B3/25 glycoprotein (Fig. 2) . In some experiments, small amounts of this lower molecular weight component could also be detected in immunoprecipitates prepared with B3/25 monoclonal antibody (Fig. 2) , and for this reason we initially thought that the 80,000 Mr protein was a structural variant of B3/25 glycoprotein that was precipitated more efficiently by the xenoantiserum than by the monoclonal antibody. Subsequent experiments showed this was not the explanation. First However, when detergent extracts of the cells were incubated with monoclonal antibody-Sepharose beads, high amounts of radioactivity were bound only to B3/25 monoclonal antibody incubated with extracts of the human cell line. A second monoclonal antibody against B3/25 glycoprotein, designated T56/ 14, gave similar results. As a specificity control, cell extracts were also incubated with T29/33 antibody-Sepharose beads. Little radioactivity was bound by this monoclonal antibody, which reacts with a high molecular weight glycoprotein of human hematopoietic cells distinct from B3/25 glycoprotein (8). As shown in Fig. 3 , the radioactivity associated with the monoclonal antibodies against B3/25 glycoprotein incubated with the human cell extract was the result of the specific binding of the 80,000 Mr horse serum component.
To Identification ofthe Serum Factor as Transferrin. The binding studies with 125I-labeled horse serum suggested that the 80,000 Mr protein bound by B3/25 glycoprotein was a major serum component, because about 0.5% of the total 125I-labeled serum protein was found bound to the antibody-Sepharose beads. Serum transferrin, the major iron transport protein, has an apparent Mr of about 80,000 and represents about 3-5% of the total serum protein (14) . We decided therefore to directly test whether transferrin binds to B3/25 glycoprotein. Because horse transferrin was not available and preliminary studies showed that human serum also contained an 80,000 Mr protein bound by B3/25 glycoprotein, binding studies were carried out with human transferrin. As shown in Table 2 , human transferrin was bound to the surface of RPMI 8402 cells and could be isolated from lysates of the cells by monoclonal antibodies against B3/25 glycoprotein. Approximately 4% of the added labeled transferrin was bound to the cells after 60-min incubation at 37°C. Of this cellassociated radioactivity, more than 25% was recovered in association with B3/25 glycoprotein bound to monoclonal antibody-Sepharose beads. This was more than 50-fold the radioactivity bound to T29/33 monoclonal antibody-Sepharose beads used as a control. NaDodSO4/polyacrylamide gel analysis confirmed that the 1251-labeled protein bound was transferrin (data not shown).
DISCUSSION
The results reported here demonstrate that the human cell surface glycoprotein previously identified by means of the B3/25 monoclonal antibody specifically binds serum transferrin and is therefore likely to be the functional cell surface transferrin receptor. Structural similarities between B3/25 glycoprotein and the transferrin receptor isolated from human placenta support this conclusion. The placental transferrin receptor is a 90,000 Mr glycoprotein that probably exists as a disulfidebonded dimer in its native state (15, 16) . The tissue distribution of transferrin receptors is also similar to that of the B3/25 glycoprotein. Transformed lymphoid cell lines have large numbers oftransferrin receptors, but few or no receptors can be detected on normal resting lymphocytes (17, 18) . After mitogenic stimulation, however, lymphocytes express transferrin receptors and the appearance of the receptors precedes the initiation of DNA synthesis (17) . Transferrin receptors have also been detected on cultured human cell lines derived from a variety of tissues but not on normal human liver or kidney membranes (19) .
The identification of B3/25 glycoprotein as the cell surface transferrin receptor thus brings together two sets of independent observations concerning the relationship ofthe cell surface to cell proliferation. Studies (20, 22) . B3/25 glycoprotein is also expressed on erythroleukemic cells (1, 22) . In addition, Judd et al. (21) found the antigen they studied on the leukemic blasts of three patients with Sezary syndrome. These observations suggest that the expression oftransferrin receptors may be characteristic of certain tumor cells growing in vivo as well as cell lines grown in vitro. Second, from our previous studies of the expression of B3/25 glycoprotein on HL-60 cells, it is clear that loss oftransferrin receptors is a relatively early event during the in vitro inducation of these cells (1) . Transferrin is required for the growth of many cell lines in vitro, including HL-60 cells (23) (24) (25) (26) , and for primary cultures of hematopoietic cells (27, 28) . Consequently, loss of transferrin receptors after exposure of HL-60 cells to inducers may be one ofthe regulatory events leading to terminal differentiation. However, because HL-60 cells are still inducible when provided with exogenous iron in the form of ferrous sulfate or ferric-fructose complexes (24) , it is unlikely that loss of transferrin receptors is the only factor limiting cell growth (unpublished data).
Despite the presence oftransferrin receptors on some normal tissues, such as placental trophoblast and maturing erythroid cells (29, 30) 
